BASF to purchase US biotechnology firm

Published: 23-Sep-2013
Ingredients Finance

Will pay approximately US$57m to strengthen position in enzyme growth market


BASF is to buy US biotechnology company Verenium for approximately US$62m (EUR48m).

Verenium is based in San Diego, California, and generated sales of US$57m in 2012.

The acquisition will strengthen BASF's footprint in the strategic enzyme growth market and is expected to close in the fourth quarter of 2013.

The deal has been approved by the Boards of Directors of both companies.

Under the terms of the merger agreement, Verenium shareholders will receive $4.00 per share, representing a 56% premium to the volume weighted average closing price of Verenium's common stock in the six months prior to announcement of the transaction.

  • Companies:
  • BASF Personal Care and Nutrition GmbH
See more

You may also like

Ingredients

Five key takeaways from LogiChem EU 2019

Read more
Having recently attended the LogiChem EU 2019 event in Amsterdam, the Netherlands, LLamasoft's Dr Madhav Durbha shares his insights from the chemical industry’s supply chain community

Trending Articles

  1. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  2. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach
  3. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Five key takeaways from LogiChem EU 2019

Having recently attended the LogiChem EU 2019 event in Amsterdam, the Netherlands, LLamasoft's Dr Madhav Durbha shares his insights from the chemical industry’s supply chain community
Ingredients

BASF completes acquisition of Chemetall

BASF has completed its acquisition of Albemarle’s global surface treatment business, Chemetall
Ingredients

BASF inaugurates new PVP production facility in Shanghai, China

Will produce PVP K30 powder used as a base for pharma excipients and cosmetics
Ingredients

Colorcon to purchase BASF’s Kollicoat IR coating system product line

The two firms will also further their cooperation to offer superior functional coatings for pharmaceutical tablets
Ingredients

BASF introduces Kollicoat MAE 100-55 for formulation of enteric film coatings

Easier handling due to dust-free material
Manufacturing

BASF establishes speciality amine production plant in Ludwigshafen

BASF’s Intermediates division develops, produces and markets more than 700 intermediates, including amines, diols, polyalcohols and acids
Ingredients

BASF to develop high purity poloxamer for Mast Therapeutics

To be used for treating specific therapeutic indications
Subscribe now